Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

136 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The somatic affairs of BRAF: tailored therapies for advanced malignant melanoma and orphan non-V600E (V600R-M) mutations.
Ponti G, Pellacani G, Tomasi A, Gelsomino F, Spallanzani A, Depenni R, Al Jalbout S, Simi L, Garagnani L, Borsari S, Conti A, Ruini C, Fontana A, Luppi G. Ponti G, et al. Among authors: luppi g. J Clin Pathol. 2013 May;66(5):441-5. doi: 10.1136/jclinpath-2012-201345. Epub 2013 Mar 5. J Clin Pathol. 2013. PMID: 23463675 Clinical Trial.
Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial.
Merle P, Blanc JF, Phelip JM, Pelletier G, Bronowicki JP, Touchefeu Y, Pageaux G, Gerolami R, Habersetzer F, Nguyen-Khac E, Casadei-Gardini A, Borbath I, Tran A, Wege H, Saad AS, Colombo M, Abergel A, Richou C, Waked I, Yee NS, Molé A, Attali P, Le Boulicaut J, Vasseur B; RELIVE Investigators. Merle P, et al. Lancet Gastroenterol Hepatol. 2019 Jun;4(6):454-465. doi: 10.1016/S2468-1253(19)30040-8. Epub 2019 Apr 4. Lancet Gastroenterol Hepatol. 2019. PMID: 30954567 Free article. Clinical Trial.
Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.
Bertolini F, Bengala C, Losi L, Pagano M, Iachetta F, Dealis C, Jovic G, Depenni R, Zironi S, Falchi AM, Luppi G, Conte PF. Bertolini F, et al. Among authors: luppi g. Int J Radiat Oncol Biol Phys. 2007 Aug 1;68(5):1455-61. doi: 10.1016/j.ijrobp.2007.02.018. Epub 2007 Apr 18. Int J Radiat Oncol Biol Phys. 2007. PMID: 17445998
Neoadjuvant treatment with single-agent cetuximab followed by 5-FU, cetuximab, and pelvic radiotherapy: a phase II study in locally advanced rectal cancer.
Bertolini F, Chiara S, Bengala C, Antognoni P, Dealis C, Zironi S, Malavasi N, Scolaro T, Depenni R, Jovic G, Sonaglio C, Rossi A, Luppi G, Conte PF. Bertolini F, et al. Among authors: luppi g. Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):466-72. doi: 10.1016/j.ijrobp.2008.04.065. Epub 2008 Nov 10. Int J Radiat Oncol Biol Phys. 2009. PMID: 19004567 Clinical Trial.
p16 immunohistochemistry of multiple primary melanomas as screening to identify Familial Melanoma Syndrome.
Ponti G, Luppi G, Losi L, Cesinaro AM, Sartori G, Maiorana A, Pellacani G, Longo C, Boni E, Pepe P, Giannetti A, Seidenari S, Landi MT. Ponti G, et al. Among authors: luppi g. Int J Dermatol. 2012 Apr;51(4):488-92. doi: 10.1111/j.1365-4632.2010.04496.x. Epub 2011 Jun 15. Int J Dermatol. 2012. PMID: 21671908 Free PMC article. No abstract available.
136 results